Orient Pharma Co., Ltd. (TPEX:4166)
Taiwan · Delayed Price · Currency is TWD 24.70
-0.35 (-1.40%)
Sep 8, 2026, 11:58 AM CST
Orient Pharma Financials Overview
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Revenue Revenue Growth | 1,516 | 1,400 | 1,223 | 889.91 | 511.86 | 463.34 |
Revenue Growth | 20.12% | 14.52% | 37.41% | 73.86% | 10.47% | 12.46% |
Gross Profit Gross Profit Growth | 852.35 | 790.72 | 651.56 | 468.67 | 155.35 | 142.67 |
Operating Income Operating Income Growth | 279.75 | 261.06 | 157.91 | 24.32 | -41.74 | -133.49 |
Net Income Net Income Growth | 235.25 | 208.44 | 107.37 | 22.29 | -28.76 | -102.65 |
Earnings Per Share EPS Growth | 0.98 | 0.90 | 0.48 | 0.10 | -0.15 | -0.55 |
EPS Growth | 174.48% | 87.89% | 381.76% | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Overseas Business Division Overseas Business Division Growth | 285.64 | 329.26 | 396.37 | 39.02 | 63.07 | 45.91 |
Taiwan Business Division Taiwan Business Division Growth | 1,231 | 1,071 | 826.45 | - | - | - |
Total Total Growth | 1,516 | 1,400 | 1,223 | 889.91 | 511.86 | 463.34 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Investments Cash & Investments Growth | 585.05 | 627.4 | 109.3 | 113.12 | 97.23 | 151.72 |
Total Debt Total Debt Growth | 189.51 | 195.95 | 546.49 | 716.9 | 508.15 | 415.01 |
Net Cash (Debt) Net Cash Growth | 395.54 | 431.45 | -437.19 | -603.78 | -410.92 | -263.29 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | 1.64 | 1.87 | -1.96 | -2.71 | -2.20 | -1.41 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Cash Flow Operating Cash Flow Growth | 291.78 | 359.86 | 195.71 | -102.99 | 11.38 | -53.57 |
Capital Expenditures CapEx Growth | -89.67 | -35.82 | -27.33 | -54.11 | -28.4 | -66.54 |
Free Cash Flow Free Cash Flow Growth | 202.11 | 324.04 | 168.38 | -157.1 | -17.01 | -120.1 |
Free Cash Flow Growth | -13.31% | 92.44% | - | - | - | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Gross Margin | 56.22% | 56.46% | 53.28% | 52.66% | 30.35% | 30.79% |
Operating Margin | 18.45% | 18.64% | 12.91% | 2.73% | -8.15% | -28.81% |
Pretax Margin | 18.89% | 17.47% | 13.34% | 2.58% | -8.03% | -23.76% |
Profit Margin | 15.52% | 14.88% | 8.78% | 2.50% | -5.62% | -22.16% |
FCF Margin | 13.33% | 23.14% | 13.77% | -17.65% | -3.32% | -25.92% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Sep '26 Sep 8, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 25.60 | 27.98 | 74.78 | 200.14 | - | - |
P/FCF Ratio | 30.12 | 18.00 | 47.69 | - | - | - |
PS Ratio | 4.02 | 4.17 | 6.57 | 5.01 | 7.64 | 7.55 |